New analysis supports long-term treatment with Ofev® in SSc-ILD patients ...Middle East

PR Newswire - News
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
RIDGEFIELD, Conn., Nov. 5, 2020 /PRNewswire/ -- Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating Ofev® (nintedanib) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The new analysis was published...

Read More Details
Finally We wish PressBee provided you with enough information of ( New analysis supports long-term treatment with Ofev® in SSc-ILD patients )

Apple Storegoogle play

Also on site :



Latest News